Fluorodopa (<sup>18</sup>F), also known as FDOPA, is a fluorinated form of L-DOPA primarily synthesized as its fluorine-18 isotopologue for use as a radiotracer in positron emission tomography (PET).
The most common side effects are injection site pain.
Fluorodopa (<sup>18</sup>F) is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adults with suspected Parkinsonian syndromes.
In October 2019, Fluorodopa (<sup>18</sup>F) was approved in the United States for the visual detection of certain nerve cells in adults with suspected Parkinsonian syndromes.
The US Food and Drug Administration approved Fluorodopa F 18 based on evidence from one clinical trial of 56 participants with suspected Parkinsonian syndromes. The trial was conducted at one clinical site in the United States.